New hope for kids with hemophilia: altuviiio trial aims to tame inhibitors
NCT ID NCT07158606
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 4 trial tests whether Altuviiio (efanesoctacog alpha) can help children with severe hemophilia A and high-titer inhibitors achieve immune tolerance. Participants also receive Hemlibra (emicizumab) to prevent bleeding. The study involves 15 children under 18 and will track success over up to 52 weeks of treatment, followed by tapering and monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
efanesoctacog alpha (Altuviiio) and emicizumab (Hemlibra)
What this could lead to
If successful, this could help children with hemophilia A and inhibitors achieve immune tolerance, reducing the need for frequent treatments and improving bleed control.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The treatment requires ongoing medication, and success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A WITH INHIBITOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Versiti Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••